经皮冠状动脉介入术前应用不同剂量氯吡格雷的疗效与安全性分析

来源 :临床合理用药杂志 | 被引量 : 0次 | 上传用户:fashion_darling
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的分析经皮冠状动脉介入术(PCI)前应用不同剂量氯吡格雷的临床效果及安全性。方法选取择期行PCI术患者78例,按照双盲法随机分为观察组和对照组各39例,观察组患者进行PCI术前服用氯吡格雷450mg,对照组患者进行PCI术前服用氯吡格雷300mg,比较2组患者血小板活化指标、血栓最大幅度(MA)、血小板抑制率、血小板聚集率及近远期不良事件发生率等。结果观察组患者CD62P、CD63及TSP等各项血小板活化指标均明显低于对照组,差异有统计学意义(P<0.01)。治疗后2组患者血小板聚集率、MAADP指标明显低于治疗前,血小板抑制率明显高于治疗前,差异均有统计学意义(P<0.05)。观察组以上指标改善情况优于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后1、6个月不良反应总发生率均低于对照组,差异有统计学意义(P<0.05)。结论PCI术前采用450mg高剂量氯吡格雷治疗相对于300mg常规剂量氯吡格雷治疗的临床效果更显著,且不良反应发生率低,是一种安全、有效的治疗方案,值得推广应用。 Objective To analyze the clinical effect and safety of different doses of clopidogrel before percutaneous coronary intervention (PCI). Methods Seventy-eight patients undergoing elective PCI were randomly divided into observation group (39 cases) and control group (39 cases). Patients in the observation group were given clopidogrel 450 mg before PCI, and patients in the control group received clopidogrel 300mg. The indexes of platelet activation, maximal thrombus (MA), platelet inhibition rate, platelet aggregation rate and the incidence of short-term and adverse events in two groups were compared. Results The indexes of platelet activation such as CD62P, CD63 and TSP in observation group were significantly lower than those in control group (P <0.01). After treatment, the platelet aggregation rate and MAADP index of two groups were significantly lower than those before treatment, the inhibition rate of platelet was significantly higher than that before treatment, the difference was statistically significant (P <0.05). The improvement of the above indexes in the observation group was better than that in the control group, the difference was statistically significant (P <0.05). The total incidence of adverse reactions in observation group was lower than that in control group at 1 and 6 months after treatment, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of high dose clopidogrel 450 mg before PCI is more significant than that of conventional clopidogrel 300 mg, and the incidence of adverse reactions is low. It is a safe and effective treatment and is worth popularizing.
其他文献
患者,男,56岁,体检发现胰尾部占位18d入院.在他院就诊,CT和MRI检查结果显示:胰尾部占位,性质待查.未予特殊处理.遂来我院就诊,门诊以“胰尾部占位”收入.既往无腹部外伤、胆
患者,男,12 岁.入院前2个月无明显诱因出现活动后胸闷、气促,且症状逐渐加重.无发热及结核病史.追问病史,患者2个月前曾经有过自行车把手撞击胸部病史.查体:右肺呼吸音消失,
患者女性,66岁.因左下腹疼痛10余天入住我科.既往有左下腹疼痛间断发作、便秘史10余年,经口服中药缓解;无外伤史或手术史.入院体检:消瘦,巩膜皮肤无黄染.心肺无异常.腹平软,
目的总结立体定向下双侧内囊前肢射频毁损术治疗难治性抽动—秽语综合征(简称TS)的临床治疗效果,并对该方法的可行性和手术风险进行分析。方法选取医院精神科收治的难治性TS
目的:观察肺曲霉菌病术后静脉应用不同疗程伏立康唑的临床治疗效果。方法选取医院实施肺曲霉菌病手术后的患者76例作为研究对象,随机分为对照组和观察组,每组38例。观察组给予持
大量研究证实肾素-血管紧张素-醛固酮系统(RAS)的激活在心房颤动(房颤)的发生、发展中起重要作用。RAS抑制剂包括血管紧张素转化酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB
目的:探讨自拟养阴活血汤治疗2型糖尿病并发冠心病的临床疗效。方法选取医院收治的2型糖尿病并发冠心病患者192例,随机分为观察组和对照组各96例,对照组应用常规西医治疗,观察组
1997年,Brugada在新英格兰杂志报道第一个心房颤动(房颤)基因座10q22-q24,从理论上证实了房颤的遗传特性。科学家们经过10余年的研究历程,从细胞、器官、整体等多层面解析了
目的采用反相高效液相色谱法(HPLC)建立复方丁苓胶囊中法莫替丁含量测定方法。方法色谱柱:Kromasil C18柱(150mm×4.6mm,5μm);流动相:庚烷磺酸钠溶液(取庚烷磺酸钠2.0g,加水
目的:研究置入起搏器5年以上患者新出现起搏器依赖及右室起搏相关心室不同步的情况。方法:选取置入时为非起搏器依赖且置入起搏器已超过5年患者272例进行随访,测量自身心率,